Orion Capital Markets Day 2017 today 18 May 2017 in Helsinki
(Thomson Reuters ONE) -
ORION CORPORATION PRESS RELEASE 18 MAY 2017 at 8:00 a.m.
EEST
Orion Capital Markets Day 2017 today 18 May 2017 in Helsinki
Orion Corporation will host Capital Markets Day for institutional investors and
analysts today, Thursday, 18 May 2017 in Helsinki. The purpose of the day is to
provide an update on the company's business, R&D projects and focus areas
including an update on the following issues:
* Orion has entered into a collaboration agreement with a South Korean
company Celltrion Healthcare for exclusive marketing, sales and
distribution rights of a biosimilar rituximab (reference product MabThera®)
in Scandinavia and Estonia in which Orion already has exclusive rights for
distribution of Celltrion Healthcare's biosimilar product Remsima®
(biosimilar infliximab, reference product Remicade®). The main indications
of MabThera® are non-hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia
(CLL) and autoimmune diseases such as rheumatoid arthritis (RA).
* Orion has become aware that generic competition of Dexdor ® has started
due to the launch of generic version of the product by a competitor in the
German market. Orion is continuing actions to defend its rights. The
effects of the generic competition on sales is difficult to estimate at
this stage.
Agenda of the CMD:
Finlandia Hall, Mannerheimintie 13, Helsinki (Veranda, ground floor)
Time 8.15 Registration and breakfast
8.55 Opening remarks
9.00 Orion's century 1917-2017 movie
9.15 Presentation by CEO Timo Lappalainen
R&D Update part I - Christer Nordstedt, SVP R&D
10.25 Break
10.45 Specialty Products update - Liisa Hurme, SVP Specialty Products
Proprietary Products update - Markku Huhta-Koivisto, SVP
Proprietary Products
11.40 Break
11.50 R&D Update part II - Christer Nordstedt, SVP R&D
Presentation by CFO Jari Karlson
12.50 Closing remarks - CEO Timo Lappalainen
13.00 Lunch
14.30 Event ends
Presentations and webcast:
All the presentations will be webcasted. As usually, link to the webcast and
presentation material will be available at http://www.orion.fi/en/cmd2017 on the
day of the event. A recording of the webcast of the event in English will be
published on the Orion website after the event.
Contact person:
Jari Karlson, CFO, Orion Corporation
tel. +358 50 966 2883
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish pharmaceutical company - a builder of
well-being. Orion develops, manufactures and markets human and veterinary
pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The
company is continuously developing new drugs and treatment methods. The core
therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS)
disorders, oncology and respiratory for which Orion developes inhaled Easyhaler®
pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the
company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq
Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 543918
Anzahl Zeichen: 4274
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 164 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Orion Capital Markets Day 2017 today 18 May 2017 in Helsinki"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
